Abstract
Objectives Several states have adopted age-based prioritization for COVID-19 vaccine eligibility (also prioritizing teachers and child care workers) because it is simple (especially when age is quantized by decade) and age is strongly associated with COVID-19 mortality. But this approach raises equity concerns based in law and ethics. This study proposes data-driven solutions for equitable policy that retains the advantages of an age-based approach.
Methods Using data from CDC and U.S. Census Bureau, I analyzed 507,227 COVID-19 deaths in the U.S. by age and race-ethnicity and compared the risk ratios to published data on risk ratios for other conditions.
Results COVID-19 mortality in the U.S. rose 2.59-fold per decade of life [95% confidence interval (2.52, 2.66)]. Down syndrome, organ transplantation, and intellectual/developmental disability have risk ratios for COVID-19 mortality that exceed that.
Conclusions People with specific conditions (including certain disabilities and certain medical conditions) associated with a risk ratio of 2.59 or 6.71 should be granted vaccine eligibility along with people 10 or 20 years older, respectively. Along with additional recommendations on data collection and reporting, this could help address equity within an age-based framework.
3-Question Summary Box
Some states have adopted age-only prioritization for COVID-19 vaccine access, quantized by decade of life, because it is simple, and age has a strong association with COVID-19 mortality. But this raises concerns based in law and ethics.
This study quantifies the age effect and documents that COVID-19 mortality increases 2.59-fold per decade of life—a smaller increase than some conditions.
People with conditions associated with at least 2.59-fold COVID-19 mortality should be granted vaccine eligibility along with people at least 10 years older.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Supported by grant 90DDUC0056 from Administration for Community Living, U.S. Department of Health and Human Services grant
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Informed consent and IRB review were not required because the data were de-identified aggregate data that are publicly available.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Changed main analysis from linear regression (which has 3-fold increase in COVID-19 mortality per decade of life) to quasipoisson regression (which has 2.6-fold increase in COVID-19 mortality per decade of life). Put linear regression in sensitivity analysis, along with quasilogistic regression (which also has 2.6-fold increase in COVID-19 mortality per decade of life). Figures and R code revised accordingly.
Data Availability
All data were downloaded from the CDC and the Census Bureau, where they are publicly available.